Molecular monitoring is important for determining whether patients are responding well to therapy
- The National Comprehensive Cancer Network® (NCCN®) and ELN have developed guidelines and recommendations for how often and what type of monitoring should be performed
- RQ-PCR is used to quantitatively assess BCR::ABL1 transcripts1
Molecular monitoring and target milestones2
European LeukemiaNet 2025 recommendations
ABL1, Abelson tyrosine kinase 1; BCR, breakpoint cluster region; ELN, European LeukemiaNet; IS, International Scale; MMR, major molecular response (BCR::ABL1IS ≤0.1%); NCCN, National Comprehensive Cancer Network; qRT-PCR, quantitative real-time polymerase chain reaction; RT-PCR, real-time polymerase chain reaction; RQ-PCR, real-time quantitative reverse transcriptase polymerase chain reaction; ACA, additional chromosome abnormalities in Ph+ cells; BCR, breakpoint cluster region; ELN, European LeukemiaNet; ELTS, European Treatment Outcome Study Long-Term Survival; IS, International Scale; MMR, major molecular response (BCR::ABL1IS ≤0.1%); NA, not applicable; Ph, Philadelphia chromosome; TFR, treatment-free remission; TKI, tyrosine kinase inhibitor.
References
National Comprehensive Cancer Network® (NCCN®), NCCN Guidelines Version 1.2026 Chronic Myeloid Leukemia. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf . Last accessed 10/9/2025
Apperley JF, Milojkovic D, Cross NC, Hjorth-Hansen H, Hochhaus A, Kantarjian H, Lipton JH, Malhotra H, Niederwieser D, Radich J, Rousselot P. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia: CHRONIC MYELOID LEUKEMIA. Leukemia. 2025 Jul 11:1-7.
Approved by Egyptian Drug Authority: HF0424OA5944/042026. Invalidation date: 20/04/2028
Kindly report any violated online promotional, educational and awareness material not having this message to The General administration for Regulation of Marketing & Advertising Materials at: www.edaegypt.gov.eg
Image
HF0424OA5944/042026 20/04/2028 |